The Food and Drug Administration issued a complete response letter to Pain Therapeutics Inc. (Nasdaq: PTIE) saying that its New Drug Application for Remoxy ER could not be approved in its current form. Shares of the biopharmaceutical plummeted $1.40 to close at $1.33.
Pain Therapeutics receives complete response letter
September 26, 2016 at 17:38 PM EDT